EIK1001 clinical trials
EIK1001 is named as an intervention in 3 current clinical trials in our USA, Germany, Spain, Belgium, Poland, Austria, South Korea, Australia, UK, France, Italy, Sweden, Denmark, Switzerland, Czechia, Norway, Portugal, Canada, Israel, Brazil and Mexico registers. 2 are recruiting patients now. The most common phase is Phase 2/3. The lead sponsor is Eikon Therapeutics. The most-studied condition is Advanced Melanoma.
Patient leaflets for EIK1001
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of EIK1001
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301 · Advanced Melanoma
|
Phase 2/3 | Recruiting | Eikon Therapeutics | UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Canada, South Korea, Australia, Israel |
|
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
|
Phase 2/3 | Recruiting | Eikon Therapeutics | USA, Germany, Spain, Belgium, Poland, Austria, Brazil, Mexico, South Korea, Australia |
|
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110 · NSCLC
|
Phase 2 | Active, closed | Eikon Therapeutics | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with EIK1001
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eikon Therapeutics | 3 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about EIK1001 trials
How many clinical trials are testing EIK1001?
3 current trials in our USA, Germany, Spain, Belgium, Poland, Austria, South Korea, Australia, UK, France, Italy, Sweden, Denmark, Switzerland, Czechia, Norway, Portugal, Canada, Israel, Brazil and Mexico registers name EIK1001 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are EIK1001 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in Germany, 2 with sites in Spain, 2 with sites in Belgium, 2 with sites in Poland, 2 with sites in Austria, 2 with sites in South Korea, 2 with sites in Australia, 1 with sites in UK, 1 with sites in France, 1 with sites in Italy, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Switzerland, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Canada, 1 with sites in Israel, 1 with sites in Brazil and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors EIK1001 clinical trials?
The lead sponsor is Eikon Therapeutics. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how EIK1001 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how EIK1001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists EIK1001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.